David Kershner, PA
Physician Assistant · Omaha, NENPI 1144304429
Payments from drug & device makers
Across 128 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Antares Pharma, Inc.$344
- Boehringer Ingelheim$245
- AbbVie$213
- Sanofi-aventis U.S. LLC$182
- Amgen$175
- Bayer$154
- plus $607 from 14 others
What the payments were for
- Food & beverage$1,82595%
- Education$965%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Antares Pharma, Inc. | 26 | $344 |
| Boehringer Ingelheim | 14 | $245 |
| AbbVie | 15 | $213 |
| Sanofi-aventis U.S. LLC | 9 | $182 |
| Amgen | 17 | $175 |
| Bayer | 9 | $154 |
| Novo Nordisk | 6 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $84 |
| Lilly USA, LLC | 5 | $71 |
| Avanir Pharmaceuticals, Inc. | 5 | $68 |
| Halozyme Inc | 3 | $54 |
| AstraZeneca(2 entities) | 2 | $38 |
| Abbott | 2 | $34 |
| Philips North America LLC | 2 | $28 |
| Merck | 2 | $26 |
| Astellas Pharma US Inc | 1 | $21 |
| Pfizer | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Radius Health, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $12 |
How this compares
$1,921 in reported general payments places this provider in the 80th percentile of 1,127 physician assistant providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 76 | $85,767 |
| OzempicSemaglutide | 53 | $80,105 |
| JardianceEmpagliflozin | 71 | $62,018 |
| EliquisApixaban | 56 | $40,494 |
| JanumetSitagliptin Phos/Metformin Hcl | 43 | $34,749 |
| JanuviaSitagliptin Phosphate | 30 | $30,509 |
| KerendiaFinerenone | 31 | $28,706 |
| MounjaroTirzepatide | 24 | $25,823 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $22,900 |
| TradjentaLinagliptin | 30 | $21,109 |
| VraylarCariprazine Hcl | 12 | $20,116 |
| GlyxambiEmpagliflozin/Linagliptin | 21 | $16,180 |
| RybelsusSemaglutide | 14 | $15,676 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $13,009 |
| LinzessLinaclotide | 23 | $12,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $71 | $111,591100 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Trijardy Xr | $245 | $103,564133 claims |
| Novo NordiskOzempic, Rybelsus | $118 | $95,78167 claims |
| MerckJanumet, Januvia | $26 | $65,25873 claims |
| PfizerEliquis | $18 | $40,49456 claims |
| AbbVieVraylar, Linzess, Synthroid | $213 | $33,82052 claims |
| BayerKerendia | $154 | $28,70631 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $182 | $22,90023 claims |
| AstraZenecaSymbicort | $38 | $13,00937 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $6,22113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,127 physician assistant providers in Nebraska.
Other physician assistant in Omaha
- Kimberly GatesOmaha$109K
- Kandice DoleshOmaha$106K
- Kathryn KestiOmaha$34K
- Sarah GretemanOmaha$24K
- Christopher BeasleyOmaha$15K
- Corrine GiggeeOmaha$12K
- Austin DuerksenOmaha$12K
- Erin HoffmanOmaha$12K
- Sara MasonOmaha$12K
- Sally CampbellOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.